Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Disease & Drugs

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Disease & Drugs

1,785 stories · every one Fact-Checked
Pridopidine early ALS findings and PREVAiLS Phase 3 clinical trial enrollment updateClinical TrialsPrilenia Reports Functional and Survival Signals for Pridopidine in ALSPrilenia Therapeutics and Ferrer reported exploratory functional, respiratory, and survival findings associated with pridopidine in 36 participants with early ALS.28 Oct 2026 · 4 min read
Fact-Checked
JELMYTO mitomycin reverse thermal gel treatment for low-grade upper tract urothelial carcinoma showing prolonged local chemotherapy delivery.Clinical TrialsUroGen’s Five-Year Data Support Durable JELMYTO ResponsesUroGen Pharma’s five-year OLYMPUS follow-up showed a median response duration of 47.8 months among 41 complete responders treated with JELMYTO.28 Oct 2026 · 4 min read
Fact-Checked
Clinical illustration representing retatrutide and semaglutide comparison for weight loss and blood glucose control in type 2 diabetes.Clinical TrialsRetatrutide Delivers 20.9% Mean Weight Loss Against SemaglutideEli Lilly reports Phase 3 TRANSCEND-T2D-2 results showing 19.5% and 20.9% mean weight loss with retatrutide 9 mg and 12 mg, respectively, versus 9.4% with semaglutide 2 mg…28 Oct 2026 · 4 min read
Fact-Checked
Zemprocitinib maintains clinical response through week 76 in the Phase III COURAGE-RA rheumatoid arthritis trial.Clinical TrialsLynk Reports Positive 76-Week Zemprocitinib Results in Rheumatoid ArthritisLynk Pharmaceuticals reports sustained zemprocitinib responses through week 76 in Phase III COURAGE-RA, with efficacy and long-term safety limitations. Written…28 Oct 2026 · 4 min read
Fact-Checked
Illustration of immune cell signalling in Sjögren’s disease and investigational CD40L antagonist dazodalibepClinical TrialsAmgen Reports Phase 3 Success for Dazodalibep in Sjögren’s DiseaseAmgen’s Phase 3 OASIZ-301 trial showed that dazodalibep significantly reduced systemic disease activity in Sjögren’s disease at Week 48 with both four-weekly and 12-weekly dosing.28 Oct 2026 · 4 min read
Fact-Checked
Illustration of topical capsaicin 8% treatment for post-surgical neuropathic pain in Grünenthal’s Phase III RISE trialClinical TrialsGrünenthal Reports Sustained Pain Reduction With QutenzaGrünenthal reported mixed Phase III results for Qutenza in post-surgical neuropathic pain. The RISE trial met its average pain-reduction endpoint over weeks 2–12, while the Week 12 endpoint…28 Oct 2026 · 4 min read
Fact-Checked
Vanda Pharmaceuticals' tradipitant reduces vomiting in a Phase 3 study of semaglutide-associated gastrointestinal effects.Clinical TrialsVanda Reports Positive Results for Tradipitant in GLP-1 VomitingVanda Pharmaceuticals’ Phase 3 Study 3601 found that tradipitant reduced vomiting following a single 1 mg semaglutide dose, with vomiting reported in 43.0% of participants versus 58.5% with…28 Oct 2026 · 4 min read
Fact-Checked
Beam Therapeutics BEAM-301 base-editing therapy targeting the genetic cause of glycogen storage disease type IaClinical TrialsBeam’s BEAM-301 Shows Early Metabolic Benefits in GSDIaBeam Therapeutics’ BEAM-301 showed early evidence of improved glucose regulation in patients with glycogen storage disease type Ia (GSDIa).28 Oct 2026 · 4 min read
Fact-Checked
Artiva Biotherapeutics discontinues AlloNK development after response durability concerns and two fatal events in its clinical programme.Clinical TrialsArtiva Ends AlloNK Development After Durability Shortfall and Two Fatal EventsArtiva Biotherapeutics has discontinued AlloNK development after updated findings showed insufficient response durability despite continued B-cell depletion and clinical activity.28 Oct 2026 · 5 min read
Fact-Checked
Scientific illustration of elranatamab targeting BCMA on multiple myeloma cells, representing Pfizer's Phase 3 MagnetisMM-32 trialClinical TrialsPfizer Reports Positive PFS Results for ELREXFIO in RRMM TrialPfizer reports that ELREXFIO (elranatamab) met the primary progression-free survival endpoint in the Phase 3 MagnetisMM-32 trial in relapsed or refractory multiple myeloma.27 Oct 2026 · 4 min read
Fact-Checked
Pelareorep and atezolizumab combination investigated for durable responses in advanced anal cancer.Clinical TrialsOncolytics Reports Promising Survival Data With Pelareorep CombinationOncolytics Biotech reported an approximately 15-month median duration of response with pelareorep plus atezolizumab in previously treated squamous cell anal cancer.27 Oct 2026 · 4 min read
Fact-Checked
Medical illustration representing fibromyalgia symptoms, pain and physical functioning assessed in Tonix Pharmaceuticals' Phase 3 TONMYA trials.Clinical TrialsTonix Reports Positive FIQR Results for TONMYA in Fibromyalgia TrialsTonix Pharmaceuticals reports Phase 3 findings showing greater improvements in patient-reported fibromyalgia symptoms and function with TONMYA versus placebo in the RELIEF and RESILIENT trials.27 Oct 2026 · 4 min read
Fact-Checked
Page 8 of 149